Breaking: Sonnet Biotherapeutics shareholders have approved a business combination with Hyperliquid Strategies Inc. The merger marks a significant corporate move in the intersection of biotech and crypto-native financial strategies. Stockholders greenlit the deal, paving the way for the two entities to formally combine operations. While details on the structure remain thin, the approval signals confidence from investors in this cross-sector partnership. The tie-up could bring fresh capital flows and strategic positioning as traditional companies increasingly eye blockchain-adjacent opportunities.